PMID- 21254871
OWN - NLM
STAT- MEDLINE
DCOM- 20120927
LR  - 20131121
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 23
IP  - 3
DP  - 2012 Jun
TI  - Cyproterone acetate or drospirenone containing combined oral contraceptives plus 
      spironolactone or cyproterone acetate for hirsutism: randomized comparison of 
      three regimens.
PG  - 177-83
LID - 10.3109/09546634.2010.519766 [doi]
AB  - OBJECTIVE: To compare the effectiveness of three different combinations of 
      combined oral contraceptives (COCs) and anti-androgens in the treatment of 
      hirsutism. METHODS: A total of 134 women with moderate and severe hirsutism were 
      randomly assigned to three treatment regimens: Group I received 30 mug of ethinyl 
      estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate 
      (CPA) (n = 45); group II received 30 mug of EE/3 mg of DRSP plus 100 mg of 
      spironolactone (n = 44); and group III received 35 mug of EE/2 mg of CPA plus 100 
      mg of CPA (n = 45), daily for 6 months. The decrease in the modified 
      Ferriman-Gallwey hirsutism score (mFGS) was the main outcome measure. RESULTS: 
      The mean decrease in mFGS after 3 and 6 months of the treatment course was 26% 
      and 49% in group I (both p < 0.01), 27% and 49% in group II (both p < 0.01), and 
      25% and 45% in group III (both p < 0.01), respectively, when compared with 
      baseline. Although the mFGS was significantly decreased in all groups, there was 
      no significant difference between groups. CONCLUSION: CPA or DRSP containing COCs 
      in combination with CPA or spironolactone have similar effects for the treatment 
      of hirsutism.
FAU - Kelekci, Kiymet Handan
AU  - Kelekci KH
AD  - Dermatology Clinic, Numune Education and Research Hospital, Seyhan Practice 
      Center, Adana, Turkey. drhandankelekci@yahoo.com
FAU - Kelekci, Sefa
AU  - Kelekci S
FAU - Yengel, Irem
AU  - Yengel I
FAU - Gul, Sule
AU  - Gul S
FAU - Yilmaz, Bulent
AU  - Yilmaz B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110122
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Androgen Antagonists)
RN  - 0 (Androstenes)
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 0 (Estrogens)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 27O7W4T232 (Spironolactone)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 4KM2BN5JHF (Cyproterone Acetate)
RN  - N295J34A25 (drospirenone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Androgen Antagonists/*therapeutic use
MH  - Androstenes/therapeutic use
MH  - Contraceptives, Oral, Combined/*therapeutic use
MH  - Cyproterone Acetate/*therapeutic use
MH  - Estrogens/*therapeutic use
MH  - Ethinyl Estradiol/*therapeutic use
MH  - Female
MH  - Hirsutism/*drug therapy
MH  - Humans
MH  - Mineralocorticoid Receptor Antagonists/*therapeutic use
MH  - Severity of Illness Index
MH  - Spironolactone/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/01/25 06:00
MHDA- 2012/09/28 06:00
CRDT- 2011/01/25 06:00
PHST- 2011/01/25 06:00 [entrez]
PHST- 2011/01/25 06:00 [pubmed]
PHST- 2012/09/28 06:00 [medline]
AID - 10.3109/09546634.2010.519766 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2012 Jun;23(3):177-83. doi: 10.3109/09546634.2010.519766. 
      Epub 2011 Jan 22.